Qureight
PrivateLast Round
Series B
Jul 29, 2026
Total Funding Raised
$31.23M
Momentum
Top 10%
of companies Caplight tracks
Company Overview
Qureight is a biotechnology company that provides an AI-powered clinical data curation and analytics platform to accelerate drug development for lung and heart diseases.
Sector
Healthcare & Life Sciences
Verticals
Clinical Trials, Medical Imaging, Medical AI, Biotechnology
Business Model
B2B
Customer Profile
Subscription SaaS, Usage-Based SaaS, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Qureight Comparables
Compare Qureight with similar companies based on industry and business-model similarity.
Qureight Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 29, 2026 | ||||
| Series A | Apr 16, 2024 | ||||
| Seed | Feb 3, 2022 | ||||
| Seed | Sep 24, 2021 |
Key People
Founding team and executive leadership
Qureight Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Ascension Ventures | Series A, Series B, Seed |
| Playfair Capital | Series A, Seed |
| Canaccord Genuity Wealth Management | Series B, Series A |
| Cambridge Angels | Series A, Seed |
| Meltwind Advisory | Series A, Series B, Seed |
| CMS Ventures | Series A, Seed |
| Hargreave Hale AIM VCT | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 20, 2026
Grew 17% QoQ, from 53 to 62 employees.
- Jul 29, 2026
$20M round led by Molten Ventures.
Recent news
Latest coverage and updates
- receives_awardOct 22, 2026
Qureight receives the Most Impactful CRO Award, sponsored by Gallagher, for its work as an end-to-end imaging CRO providing enterprise-grade imaging and precision endpoints for clinical trials focused on lung and heart disease.
- signs_new_clientOct 20, 2026
Celea Therapeutics, Inc. contracts Qureight as the end-to-end imaging CRO for its phase 3 SURPASS-IPF trial, building on their Phase 2b work.
- expands_offices_toAug 19, 2026
Qureight expanded offices to London, United Kingdom, Northern Europe, Europe on Aug 19th '26.
- is_developingAug 5, 2026
Qureight is developing SCA to evaluate inhaled pirfenidone for idiopathic pulmonary fibrosis on Jul 1st '25.
- receives_financingAug 3, 2026
Qureight received financing of $2.69M on Mar 1st '26.
Qureight Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Qureight's valuation, stock price, and market status.
Is Qureight a public or private company?
Qureight is a private company.
What is the current stock price of Qureight?
Qureight is a private company, so its shares have no public market price. Caplight tracks Qureight's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Qureight worth (valuation)?
Valuation information for Qureight is not publicly available.
Can I buy Qureight stock?
Qureight shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Qureight's last funding round?
Qureight's most recent funding round was Series B on July 29, 2026.
Who are the main investors in Qureight?
Key investors in Qureight include Playfair Capital, Canaccord Genuity Wealth Management, Hargreave Hale AIM VCT, Molten Ventures.
Will Qureight IPO soon?
No public IPO plans have been announced for Qureight.
How can I track Qureight secondary market activity?
Caplight tracks bids, offers, and trades in Qureight's shares on secondary markets.